Previous Article | Next Article 
Molecular and Cellular Biology, February 2001, p. 1336-1344, Vol. 21, No. 4
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.2001.21.4.1336-1344.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Analysis of SM22
-Deficient Mice Reveals
Unanticipated Insights into Smooth Muscle Cell Differentiation
and Function
Janet C. L.
Zhang,1
Steven
Kim,2
Brian P.
Helmke,3
William W.
Yu,1
Kevin L.
Du,1
Min Min
Lu,1
Mark
Strobeck,1
Qian-Chun
Yu,4 and
Michael S.
Parmacek1,*
Departments of
Medicine,1
Bioengineering,3 and Cell and
Molecular Engineering,4 University of
Pennsylvania, Philadelphia, Pennsylvania 19104, and Department
of Medicine, University of Chicago, Chicago, Illinois
606372
Received 17 October 2000/Accepted 7 November 2000
 |
ABSTRACT |
SM22
is a 22-kDa smooth muscle cell (SMC) lineage-restricted
protein that physically associates with cytoskeletal actin filament bundles in contractile SMCs. To examine the function of SM22
, gene
targeting was used to generate SM22
-deficient
(SM22
/
LacZ) mice. The gene targeting strategy employed
resulted in insertion of the bacterial lacZ reporter gene
at the SM22
initiation codon, permitting precise analysis of the
temporal and spatial pattern of SM22
transcriptional activation in
the developing mouse. Northern and Western blot analyses confirmed that
the gene targeting strategy resulted in a null mutation. Histological
analysis of SM22+/
LacZ embryos revealed detectable
-galactosidase activity in the unturned embryonic day 8.0 embryo in
the layer of cells surrounding the paired dorsal aortae concomitant
with its expression in the primitive heart tube, cephalic mesenchyme,
and yolk sac vasculature. Subsequently, during postnatal development,
-galactosidase activity was observed exclusively in arterial,
venous, and visceral SMCs. SM22
-deficient mice are viable and
fertile. Their blood pressure and heart rate do not differ
significantly from their control SM22
+/
and
SM22
+/+ littermates. The vasculature and SMC-containing
tissues of SM22
-deficient mice develop normally and appear to be
histologically and ultrastructurally similar to those of their control
littermates. Taken together, these data demonstrate that SM22
is not
required for basal homeostatic functions mediated by vascular and
visceral SMCs in the developing mouse. These data also suggest that
signaling pathways that regulate SMC specification and differentiation
from local mesenchyme are activated earlier in the angiogenic program
than previously recognized.
 |
INTRODUCTION |
Smooth muscle cells (SMCs) subserve
a variety of functions in higher vertebrates, including the regulation
of arterial tone, the control of airway resistance, and the modulation
of gastrointestinal and genitourinary tract contractility and basal
tone. Despite the myriad of functions mediated by SMCs, relatively
little is understood about the developmental programs that regulate SMC specification and differentiation. This is due, in part, to the complex
embryological origins of the SMC lineage(s) and the lack of
definitive SMC markers (27, 28). In contrast to striated muscle cells which terminally differentiate, SMCs retain their capacity
to proliferate and modulate their phenotype during postnatal development (27, 34, 36, 37). This characteristic
presumably evolved to facilitate reparative processes such as wound
healing. However, it has also been implicated in the
pathophysiology of a number of disease processes, including
hypertension, restenosis following angioplasty, posttransplant
arteriopathy, and asthma (13, 25, 32, 34).
Cytoskeletal dynamics and organization play an important role in
regulating SMC morphology and phenotype (for a review, see reference
41). The SMC cytoskeleton is composed of actin filaments, as well as intermediate filaments and their associated proteins. The
insoluble network of intermediate filaments has been implicated in the
maintenance of SMC shape (42). The intermediate filaments colocalize with a subpopulation of F-actin filament bundles that is
distinct from the contractile apparatus (26). The
cytoskeletal actin filaments and smooth muscle actin converge upon
-actinin-containing dense bodies that serve as a possible coupling
point between the SMC contractile apparatus and the cytoskeleton
(26). Cytoskeletal actin filaments are anchored within
focal adhesions which form rib-like arrays over the entire SMC surface
(40). The geometric organization of these arrays assures
that contractile tension is distributed uniformly over the SMCs to the
extracellular matrix.
SM22
is a 22-kDa cytoskeletal protein that is expressed abundantly
and exclusively in visceral and vascular SMCs during postnatal development. SM22
has been variably designated SM22
(17,
37), transgelin (16), WS3-10 (45), and
p27 (1). SM22
mRNA has been detected in the dorsal
aorta of the mouse embryo as early as embryonic day 9.5 (E9.5)
(18). Like most other markers of the SMC lineage, SM22
is also expressed in embryonic cardiac and skeletal muscle through
mid-gestation (6, 17, 18, 37). SM22
is downregulated in
concert with other SMC-restricted myofibrillar proteins in late-passage
primary aortic SMCs and in neointimal SMCs that arise in response to
arterial injury (35, 36). In human atherosclerotic
lesions, SM22
is downregulated within neointimal SMCs but is
expressed in SMCs that form the fibrous caps of complicated atherosclerotic lesions (35, 36). Our group, and others,
reported that the mouse SM22
promoter restricts transgene expression
to arterial SMCs, suggesting that distinct transcriptional programs may
distinguish previously unrecognized SMC sublineages (14, 19, 22,
43). The activity of the mouse SM22
promoter is critically
dependent upon two CArG box-containing elements that bind the MADS box
transcription factor SRF (14, 19, 22, 43).
Despite the fact that SM22
is expressed abundantly in SMCs and has
been localized within the cytoskeletal apparatus, relatively little is
understood about its function. SM22
shares high-level amino acid
sequence identity with several other proteins, including the thin
filament SMC-restricted myofibrillar regulatory protein calponin
(33, 44), the Caenorhabditis elegans body wall
muscle protein Unc-87 (8), the Drosophila
muscle protein Mp20 (2), and the neuronal-restricted
protein NP25 (31). Mutation of the unc-87 and
mp20 genes results in paralysis of the C. elegans
body wall and of the Drosophila flight muscle, respectively
(2, 8). SM22
colocalizes to actin filament bundles and
stress fibers (41). Purified SM22
protein binds
directly to actin filaments at a ratio of 1:6 actin monomers (38,
39). These data suggest that SM22
may serve to organize the
spatial relationships of actin filaments in SMCs (38, 39,
41). In this regard, it is also noteworthy that SM22
gene
expression is downregulated when vascular SMCs assume a synthetic
phenotype and by cellular transformation processes that involve major
cytoskeletal rearrangements (35, 37). Taken together,
these data suggest that SM22
may play a role in organization of the
cytoskeleton and directly, or indirectly, regulate SMC morphology or
other processes involving the cytoskeleton.
In the studies described here, gene targeting was used to define
precisely the spatial and temporal patterns of SM22
transcriptional activation during vascular development and to examine the function of
the SM22
protein in SMCs. Surprisingly, in E8.0
SM22+/
LacZ embryos
-galactosidase activity was
observed in the dorsal aorta. This is 24 to 36 h prior to the
documented expression of genes encoding vascular SMC markers in the
embryonic mouse. During postnatal development, SM22
gene was
activated exclusively in visceral and vascular SMCs. SM22
-deficient
embryos (SM22
/
) are viable and fertile and develop
normally. SMC-containing tissues from SM22
-deficient mice are
histologically indistinguishable from the tissues of their control
littermates, and only subtle defects in the arrangement of actin
filaments are observed in SM22
-deficient SMCs. These data
demonstrate that SM22
is not required for the normal development of
the mouse embryo and basal homeostatic functions mediated by SMCs. In
addition, these data demonstrate that the devleopmental program leading
to vascular stabilization and patterning during embryonic development
is initiated earlier than was suggested by previous studies.
 |
MATERIALS AND METHODS |
Molecular cloning and generation of SM22
mutant embryonic stem
(ES) cells and mice.
A genomic clone including the 5' end of the
murine SM22
gene was isolated from an SV129 mouse library
(43). The targeting vector was generated in the pPNT
plasmid (46), which contains the PGK-neo-poly(A) and
PGK-tk-poly(A) cassettes for positive and negative selection,
respectively. As schematically represented in Fig.
1A, the pPNTSM22.LacZ targeting vector
contains a genomic subfragment that includes approximately 5-kb of the
SM22
5' flanking sequence, exon 1, intron 1, and exon 2 sequence
through the initiation codon (denoted as ATG). This was cloned in frame
to the bacterial lacZ reporter gene (denoted as LacZ), which
in turn was subcloned into NotI/XhoI-digested
pPNT. The targeting vector also includes the 2.6-kb
BamHI/NcoI SM22
genomic subfragment that spans
exon 4 through intron 5 sequences subcloned into the EcoRI
site of pPNT. In pPNTSM22.LacZ, sequences 3' of the initiation codon of exon 2 are replaced by the lacZ reporter gene and the
PGK-neo cassette.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 1.
Targeted disruption and insertion of lacZ
gene into the SM22 gene. (A) Schematic representation of the SM22
targeting strategy. (Top) Partial restriction endonuclease map of the
murine SM22 genomic locus showing BamHI (B) and
EcoRI (R1) sites. Exons are shown in black. (Middle) SM22
targeting vector containing the neomycin resistance (neo)
and herpes simplex virus thymidine kinase (tk) genes under
the control of the PGK promoter. (Bottom) Structure of the targeted
mutant SM22 allele and location of the probe used in Southern blot
analyses. (B) Southern blot analysis of DNA prepared from the offspring
of SM22+/ LacZ × SM22+/ LacZ mating. DNA was
digested with EcoRI and hybridized to the radiolabeled
SM22 genomic probe shown in Fig. 1A. The positions of the wild-type
(14-kb) and targeted (10-kb) allele are indicated with arrows at left.
(C) (Top) Northern blot analysis of SM22 gene expression in aortic
RNA harvested from wild-type (+/+), heterozygous (+/ ), and
homozygous-null ( / ) mice. (Bottom) Loading and integrity of RNA was
assessed by ethidium bromide staining of the 28S RNA in the gel prior
to membrane transfer. (D) Western blot analysis of protein lysates
prepared from the aorta of wild-type (+/+), heterozygous (+/ ), and
homozygous-null ( / ) mice. Protein was fractionated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to
Immobilon-P membrane, incubated with rabbit -mouse SM22
polyclonal antiserum, and visualized with goat anti-mouse horseradish
peroxidase-coupled secondary antibody. The 22-kDa marker is shown to
the right.
|
|
The SM22

targeting construct was linearized with
NotI and
electroporated into RW ES cells as described previously
(
24).
After 24 h, neomycin-resistant transfectants
were selected in
250 µg of G418 per ml and 1 µM gancyclovir for 8 to 10 days. DNA
from resistant ES cell clones was analyzed by Southern
blot analysis
after
EcoRI digestion with a radiolabeled
probe derived from genomic
sequences located 3' of the targeting vector
(see Fig.
1A). To
generate SM22

-deficient mice, ES cells from two
independently
derived SM22
+/
LacZ clones were
microinjected into C57BL/6 donor blastocysts that
were implanted into
pseudopregnant CD1 females (
3,
12). The
resulting male
chimeras were mated with C57BL/6 females, and agouti
offspring were
genotyped by Southern blot analysis as described
previously
(
24). SM22
+/
LacZ mice were then outbred with
C57BL/6 and CD1 mice to generate
heterozygous SM22
/
LacZ
mice that were interbred for phenotype analysis. All animal
experimentation
was performed according to National Institutes of
Health guidelines
in the University of Pennsylvania Animal Care
Facility.
Preparation of SM22
polyclonal antiserum.
The
pGEX4TSM22
expression plasmid encoding the glutathione
S-transferase (GST)-mouse SM22
(amino acids 1 to 201)
fusion protein was transformed into bacteria, and GST-SM22
fusion
protein was induced and purified from bacterial extracts as described previously (23). Rabbits were immunized with the purified
GST-SM22
fusion protein according to the standard protocol of
Cocalico Biologicals, Inc. (Reamstown, Pa.). Preimmune
immunoglobulin G (IgG) and anti-SM22
polyclonal IgG (no. 1387-4)
were isolated from the serum by GST-SM22
affinity chromatography and
protein A-Sepharose chromatography.
Northern and Western blot analyses.
RNA was isolated from
tissues of wild-type, heterozygous SM22+/
LacZ, and
homozygous SM22
/
LacZ mice as described elsewhere
(24). Northern blot analyses were performed using 10 µg
of RNA/sample, and the radiolabeled 754-bp (bp 29 to 811) mouse SM22
cDNA probe as described previously (29). Western blot
analyses were performed as described earlier using the
affinity-purified rabbit polyclonal
-SM22
antiserum and control
rabbit preimmune IgG (17).
Cardiovascular physiological assessment.
The systolic blood
pressure (SBP) and heart rate (HR) of conscious wild-type, heterozygous
(SM22+/
LacZ), and homozygous-null
(SM22
/
LacZ) adult male mice were compared using a mouse
physiological recording system according to the manufacturer's
instructions (Visitech System, Apex, N.C.). Each measurement was
performed in triplicate and was repeated the following day to ensure
reproducibility. To assess cardiac function in wild-type, heterozygous
(SM22+/
LacZ), and homozygous-null
(SM22
/
LacZ) adult male mice, echocardiography was
performed using an S12 transducer (5 to 12 MHz) and a HP5500 Sonos
system as described earlier (7). M-mode tracings were made
at the level of the papillary muscle in the left ventricular (LV)
short-axis view. The heart rate was determined from the M-mode and
pulsed-Doppler tracings of the peak aortic flow velocity in the
ascending aorta. On-line measurement of LV dimensions was made using a
Tom Tec Imaging System. End-systolic and diastolic dimensions were
determined by plainimetry. The percent left ventricular fractional
shortening was calculated using a standard formula: [(LVEDd
LVESd)/LVEDd] × 100. The percent ejection fraction was estimated from
the fractional area change (FAC) in the LV short-axis view as follows:
FAC = [(LVEDa
LVESa)/LVEDa] × 100. Color flow mapping
and pulsed Doppler wave forms were obtained across the pulmonary artery
to evaluate patent ductus arteriosus. The statistical significance was
calculated by analysis of variance ANOVA and by two-tailed unpaired
Student t test (a P value of <0.05 was
considered significant).
Cell biology, histology, and ultrastructural analyses.
Tissues from adult wild-type and SM22
/
LacZ mice were
fixed, embedded in paraffin, sectioned, and stained with hematoxylin
and eosin as described previously (24). Embryos and tissue
sections from adult mice were fixed and stained for
-galactosidase
activity and counterstained with hematoxylin and eosin as described
previously (5). A7r5 SMCs were stably transfected with an
expression plasmid encoding Ds-RED epitope-tagged mouse SM22
as
described previously (15). Three-dimensional (3-D)
fluorescence images of A7r5 cells and primary SMCs were acquired using
a Delta Vision microscopy system (Applied Precision, Issaquah, Wash.)
equipped with an appropriate barrier filter set (Chroma, Battleboro,
Vt.) for Ds-Red or rhodamine (
ex = 555 nm,
em = 617 nm). Spatial and temporal normalization of
the illumination intensity allowed quantitative analysis of the
fluorescence intensity (11). A constrained iterative
deconvolution algorithm (11) using an experimentally
measured point spread function was applied to 3-D arrays of optical
sections to yield a high-resolution spatial distribution of
fluorescence intensity that accurately represented the 3-D cytoskeletal
structure (9). Image restoration and volume projections
were computed using SoftWoRx software (Applied Precision). For electron
microscopy, the aorta and bladder from wild-type and
SM22
/
LacZ mice were fixed in 2.5% glutaraldehyde and
2% paraformaldehyde and then postfixed with 2% aqueous osmium
tetroxide as described previously (4). The samples were
washed and dehydrated with ethanol and embedded in LX-112 medium that
was polymerized at 70°C for 48 h. Ultrathin sections (80 nm)
were cut with a diamond knife and stained with uranyl acetate.
Immunogold labeling of tissue sections was performed as described
previously (4). Samples were fixed with 2%
paraformaldehyde and 0.05% glutaraldehyde in phosphate-buffered saline
for 1 h, treated with 10 mM NH4Cl for 30 min,
dehydrated at
20°C, and embedded in Lowicryl K4M medium. The
samples were polymerized with UV light (365 nm), and ultrathin
sections (90 nm) were cut, mounted on Formvar-coated nickel grids,
blocked with 1% bovine serum albumin and 2% goat serum, and incubated
with affinity-purified anti-SM22
polyclonal antiserum or control
rabbit IgG at a 1:100 dilution. The sections were then incubated with
15-nm gold-conjugated anti-rabbit IgG and stained with uranyl acetate,
and the images were visualized with a Philips CM100 electron microscope
at 60 kV.
 |
RESULTS |
Targeted disruption of the SM22
gene and insertion of
lacZ in ES cells and mice.
To produce a targeted
disruption and insertion of the lacZ reporter gene in the
mouse SM22
locus, a targeting vector was constructed in which the
lacZ gene was inserted in-frame at the SM22
initiation
codon (ATG), and the remainder of exon 2, intron 2, exon 3, and part of
intron 3 were replaced with the phosphoglycerokinase-neomycin (neo) cassette (Fig. 1A). The linearized targeting vector
was electroporated into RW ES cells. Of 89 G418- and
gancyclovir-resistant ES cell colonies screened, 6 were shown to be
homologous recombinants by Southern blot analyses. Each of these
SM22+/
LacZ clones contained a single site of integration
of the vector in the host genome as determined by Southern blot
analyses performed with a neo probe (data not shown).
Two independently derived SM22
+/
LacZ ES cell lines were
used to generate chimeric mice, and these mice were crossed to
C57BL/6 mice
to transmit the targeted allele through the germ line
as determined
by Southern blot analysis (Fig.
1B). Heterozygous
SM22
+/
LacZ mice were phenotypically normal and fertile.
These mice were
outbred to the BL/6 and CD1 background to produce
heterozygotes
that were intercrossed to generate homozygous
SM22
/
LacZ mice. To confirm that a null mutation was
created with this targeting
strategy, Northern blot analyses were
performed on RNA isolated
from SMC-containing tissues (aorta and
uterus) harvested from
wild-type (SM22
+/+), heterozygous
(SM22
+/
LacZ), and homozygous (SM22
/
LacZ)
null mice. As anticipated, a 1.3-kb transcript corresponding
to the
expected size of SM22

mRNA was observed in samples of
RNA prepared
from the aorta (Fig.
1C, lanes 1 and 2) and uterus
(data not shown) of
wild-type and heterozygous mice. In contrast,
hybridization of the
radiolabeled SM22

cDNA probe to RNA samples
prepared from the
tissues of SM22
/
LacZ mice was not detected (Fig.
1C,
lane 3). Western blot analyses
performed with SM22

-specific
polyclonal antiserum and tissue
lysates prepared from the aorta of
wild-type (SM22
+/+), heterozygous
(SM22
+/
LacZ), and homozygous (SM22
/
LacZ)
null mice revealed the expected 22-kDa band (Fig.
1D, lanes
1 and 2).
In addition, a 20-kDa signal was reproducibly observed
in lysates
prepared from the aorta of wild-type (SM22
+/+) and
heterozygous (SM22
+/
LacZ) mice. In contrast, no
hybridization signal was detected in tissue
lysates prepared from the
aorta (Fig.
1D, lane 3) and uterus (data
not shown) of homozygous
SM22
/
LacZ null mice. Taken together, these data
demonstrate that the gene
targeting strategy utilized generated a null
mutation in the gene
encoding SM22

.
Transcriptional activation of the SM22
gene in the embryonic and
adult mouse.
The gene targeting strategy effectively knocked in
the bacterial lacZ reporter gene under the transcriptional
control of the endogenous SM22
promoter, as well as other
unidentified elements flanking and within the SM22
gene. To
determine when and where in the postgastrulation embryo the SM22
gene is transcribed, E8.0 SM22+/
LacZ embryos were
harvested from staged matings of SM22+/
LacZ × SM22+/
LacZ mice and stained for
-galactosidase activity. At E8.0, the process of "embryonic
turning" is initiated, the heart consists of common atrial and
ventricular chambers, and the unfused dorsal aortae are easily
recognizable. In the E8.0 SM22+/
LacZ embryo,
-galactosidase activity (blue staining) was obvious within the head,
heart, cardiac outflow tract, dorsal aorta, and yolk sac membranes
(Fig. 2A). Sections obtained through the
headfold revealed that lacZ-positive cells were restricted
to the cephalic mesenchyme (Fig. 2B). No staining was observed within
the neuroepithelium or surface ectoderm (Fig. 2B). Sections through the
superior thoracic cavity revealed blue-stained pericardial and
myocardial cells. In contrast, the single layer of endocardial cells
did not express
-galactosidase (Fig. 2C). In addition, blue-stained
cells were reproducibly observed surrounding the paired dorsal aorta
(Fig. 2C and D, A.). Of note, this is 24 to 36 h prior to the
reported expression of genes encoding SMC markers in the mouse embryo
(27). Finally, scattered blue stained cells were observed
within the paraxial mesoderm (Fig. 2D), which gives rise to the somites
and in the notochord (Fig. 2C).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 2.
The SM22 gene is activated in the dorsal aorta of the
E8.0 embryo. E8.0 SM22+/ LacZ embryos harvested from
staged matings of SM22+/ LacZ × SM22+/ LacZ
mice genotyped by Southern blot analyses and stained for
-galactosidase activity as described in Materials and Methods. (A)
Whole-mount -galactosidase activity in an E8.0
SM22+/ LacZ embryo. -Galactosidase activity (blue
staining) is observed in the embryonic heart, aorta, cephalic
mesenchyme (CM), and yolk sac. The planes of the sections shown in
panels B, C, and D are indicated by white lines. (B) Cross-section
through the head of an E8.0 SM22+/ LacZ embryo showing
-galactosidase activity restricted to cells within the cephalic
mesenchyme (CM). Staining was not observed in the surface ectoderm
(ECT) or neuroepithelium (NE). (C) Cross-section through the thoracic
cavity of an E8.0 SM22+/ LacZ embryo demonstrating
-galactosidase activity in the myocardium (Myo), pericardium (P),
aorta (Ao), and notochord (NC). (D) High-power view of a section
through the thoracic cavity of an E8.0 SM22+/ LacZ embryo
demonstrating -galactosidase activity in cells surrounding the
paired dorsal aorta (Ao). In addition, faint blue staining is observed
in scattered cells within the paraxial mesoderm (PM), which gives rise
to the somites.
|
|
Histochemical analyses of adult SM22
+/
LacZ mice revealed,
as anticipated,

-galactosidase activity (blue-stained cells) in the
tunica
media of the major and branch arteries, including the aorta
(Fig.
3A) and the diaphragmatic arteries
(Fig.
3B). Blue staining was
also observed within arterioles (Fig.
3C,
arrow) located within
the kidneys and other tissues. This pattern of
expression recapitulated
the pattern of
lacZ expression
observed in transgenic mice harboring
the mouse SM22

promoter
(
14,
19,
22). However, in contrast
to the pattern of

-galactosidase activity observed in SM22

promoter-driven
transgenic mice, the coronary arteries, which have a unique
embryological
derivation, also stained dark blue (Fig.
3D). Similarly,
venous
(Fig.
3E) and visceral SMCs, including those in the bladder
(Fig.
3F), intestine (Fig.
3G), and stomach (Fig.
3H), as well as the
bronchial SMCs (Fig.
3I, Br), were

-galactosidase positive in
SM22
+/
LacZ mice. Taken together, these data demonstrate
that the SM22

gene
is activated at least 24 to 36 h prior to
the documented expression
of SMC markers in presumptive vascular SMCs.
In addition, these
data demonstrate that the knock-in of the
lacZ gene into the endogenous
SM22

locus restricts

-galactosidase gene expression to vascular
and visceral SMCs during
postnatal development in the mouse.

View larger version (79K):
[in this window]
[in a new window]
|
FIG. 3.
-Galactosidase activity in SM22+/ LacZ
mice is restricted to vascular and visceral SMCs. Tissues were
harvested from SM22+/ LacZ mice, fixed, stained with X-Gal
(5-bromo-4-chloro-3-indolyl- -D-galactopyranoside) and counterstained
with hematoxylin and eosin as described in Materials and Methods.
-Galactosidase activity (blue staining) was observed in the tunica
media of the aorta (A), the diaphragmatic arteries (B), the tunica
media of resistance arterioles (arrow) within the kidneys (C), the
right coronary artery (D), veins (E), the muscular wall of the bladder
(F), the lamina propria of the small intestine (G), and the muscular
wall of the stomach (H), as well as in bronchial SMCs (Br) surrounding
the bronchial epithelium (EP) (I).
|
|
Analyses of SM22
-deficient mice.
As shown in Table
1, among 127 live-born offspring from
SM22+/
LacZ × SM22+/
LacZ matings, 32 wild-type (SM22+/+), 55 heterozygous
(SM22+/
LacZ), and 40 homozygous
(SM22
/
LacZ)-null mice were generated. This ratio does
not differ significantly from the expected Mendelian distribution,
demonstrating that SM22
-deficient mice survive to birth. The weight
of age-matched littermates also did not differ significantly between
wild-type, heterozygous, and SM22
-null mice. In addition, the SBP
and HR of conscious adult wild-type (SM22+/+) and
SM22
-deficient mice (SM22
/
LacZ) did not differ
significantly (Table 1). Taken together, these data suggest that
SM22
is not required for basal homeostatic functions mediated by
SMCs in the developing mouse.
To determine whether SM22

was required for the normal development of
the mouse, tissues obtained from SM22

-deficient mice
and their
control littermates were compared (Fig.
4). As shown
in Fig.
2, the SM22

gene
is expressed at high levels in the embryonic
heart. However, hearts
obtained from SM22

-deficient mice were
indistinguishable from their
control littermates (compare Fig.
4A and B). Moreover, the results of
an echocardiographic comparison
of chamber size, ventricular wall
thickness, and indices of contractile
function, including left
ventricular fractional shortening and
ejection fraction, did not differ
significantly (data not shown).
Similarly, the arteries and veins of
wild-type and SM22

-deficient
adult mice were virtually
indistinguishable, including quantitative
morphometric analyses of the
arterial intima to media ratios (compare
Fig.
4C and D). In addition,
visceral organs obtained from wild-type
and SM22

-deficient mice,
including the small intestine (compare
Fig.
4E and F) and uterus
(compare Fig.
4G and H), developed normally
and were histologically
indistinguishable.

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 4.
SMC-containing tissues develop normally in
SM22 -deficient mice. Tissues harvested from wild-type (wt) and
SM22 -deficient ( / ) mice were fixed and stained with hematoxylin
and eosin as described in Materials and Methods. (A and B) Comparison
of hearts from wild-type (A) and / (B) mice demonstrating normal
left ventricular (LV) and right ventricular (RV) chamber dimensions and
morphology. (C and D) Comparison of the aorta harvested from a
wild-type (C) and / (D) adult mouse demonstrating normal tunica
intima (End), tunica media (M), and adventitia (AD). (E and F)
Comparison of small intestine harvested from wild-type (E) and /
(F) mice demonstrating intact lamina propria and intestinal epithelium
(EP). (G and H) Comparison of uterus harvested from wild-type (G) and
/ (H) mice demonstrating normal SMC arrangement within the muscular
layers (SMCs) of the uterus.
|
|
Ultrastructural analyses of SM22
-deficient SMCs.
SM22
colocalizes to the cytoskeleton of SMCs (38, 39, 41).
Therefore, it was of interest to define the subcellular localization of
SM22
in SMCs and to determine whether SM22
-deficient SMCs
exhibited alterations in cytoskeletal architecture. A 3-D reconstruction of A7r5 SMCs that stably expressed a Ds-Red-tagged SM22
protein revealed localization to the F-actin filament bundles (Fig. 5A). This pattern of expression was
identical to that observed when these cells were stained with the
actin-binding protein phalloidin (data not shown). Immunogold
localization of SM22
protein performed using affinity-purified
SM22
polyclonal antiserum revealed gold particles (black dots)
localizing to longitudinally oriented actin filaments in the cytoplasm
and patches at the cell periphery (Fig. 5B). In addition, gold-labeled
SM22
protein was also observed on the surface of some myosin bundles
(dark patches in Fig. 5B). Signal (black dots in Fig. 5B) was not
detected in the extracellular space, fibroblasts, or endothelial cells
(data not shown). Hybridization to actin filaments (or other
subcellular structures and organelles) was not observed in control
experiments performed by substituting rabbit IgG for affinity-purified
rabbit anti-SM22
IgG. These data confirm that SM22
is a component
of the SMC cytoskeleton that colocalizes localizes with filamentous
actin.

View larger version (129K):
[in this window]
[in a new window]
|
FIG. 5.
Cytoskeletal organization of wild-type and
SM22 -deficient SMCs. (A) Cellular localization of Ds-Red-tagged
SM22 in A7r5 SMCs. 3-D fluorescence images of A7r5 cells that stably
express Ds-RED epitope-tagged SM22 were acquired using a Delta
Vision micrscopy system, and image restoration and volume projections
were computed as described in Materials and Methods. SM22 protein
(white lines) localized to actin filament bundles. (B) Subcellular
distribution of SM22 in the intact mouse aorta. Ultrathin sections
of mouse aorta were incubated with affinity-purified anti-SM22
polyclonal antiserum. The sections were then incubated with
gold-conjugated anti-rabbit IgG and stained with uranyl acetate. The
anti-SM22 antibody (black dots) hybridized to longitudinally
oriented actin filaments located throughout the cytoplasm and at the
cell periphery. (C and D) 3-D fluorescence images of primary mouse
aortic SMCs isolated from a wild-type (C) and SM22 -deficient (D)
mouse stained with rhodamine-labeled phalloidin. Actin filament bundles
(white lines) form well-organized rib-like arrays in the
SM22 -deficient mouse ( / , D) and its control littermate (+/+, C).
No significant differences in fluorescence intensity in staining were
detected. Bar, 1 µm. (E and F) Ultrastructural comparison of SMCs in
the intact bladder of wild-type (E) and SM22 -deficient (F) mice. The
bladder was fixed, embedded, sectioned, and stained, and images were
generated with a Philips CM-100 electron microscope as described in
Materials and Methods. Compared to the SMCs in the wild-type bladder
which demonstrate obvious well-spaced, longitudinally oriented actin
filaments (+/+, F), the cytoplasm of SM22 -deficient SMCs appears to
be homogeneous, reflecting differences in spacing of the actin
filaments. This resulted in more-condensed-appearing cytoplasmic
bundles (arrows). Magnification, ×104,125.
|
|
To determine whether SM22

-deficient SMCs display normal cytoskeletal
organization, 3-D fluorescence images of primary aortic
SMCs isolated
from wild-type (SM22
+/+) and SM22

-null
(SM22
/
LacZ) mice were stained with
rhodamine-conjugated phalloidin and then
compared after
deconvolution and image restoration. In both wild-type
aortic SMCs
(Fig.
5C) and SM22

-deficient SMCs (Fig.
5D), rib-like
arrays of
actin filament bundles were observed throughout the
cytoplasm.
Consistent with this observation, no significant differences
were
observed in the pattern of

-actinin, desmin, and

-tubulin
expression in aortic SMCs isolated from wild-type and SM22

-deficient
mice (data not shown). Electron microscopic examination of
SM22

-deficient
SMCs within the tunica media of the aorta and the
bladder revealed
no obvious ultrastructural abnormalities (compare Fig.
5E and
F). There were no signs of cell death, degeneration, or
fragmentation
in SM22

-deficient SMCs. SM22

-null SMCs demonstrated
a centrally
located nucleus, normal organelle content and
structure, and an
intact plasma membrane with marginal
vesicles (data not shown).
Many of the wild-type and
SM22
/
LacZ SMCs showed indentation of the nuclear
envelope caused by muscular
contraction. All of the SM22

-deficient
SMCs contained abundant
cytoskeletal filaments in the form of
nonbanding bundles that
ran parallel to the longitudinal axis of the
cells. In addition,
dense bodies were observed within the cytoplasm and
at the cell
periphery. The only discernible difference observed between
wild-type
(+/+) and SM22

-deficient (

/

) SMCs was the more
homogeneous
appearance of the cytoplasm in SM22

-deficient SMCs that
reflects
a difference in the spacing of myofilaments. This resulted in
condensed-appearing ctyoplasmic bundles in SM22

-deficient SMCs
within the bladder (arrow in Fig.
5F) and aorta (data not shown).
Taken
together, these data demonstrate that targeted mutation
in the gene
encoding SM22

does not result in a gross disruption
of cytoskeletal
organization.
 |
DISCUSSION |
SM22
is a cytoskeletal protein that is expressed abundantly and
exclusively in SMCs during postnatal development. In the studies
described here, gene targeting was used to generate mice harboring a
null mutation in the gene encoding SM22
and insertion of the
lacZ gene into the SM22
locus. Analyses of heterozyogous SM22+/
LacZ embryos revealed that the SM22
gene is
transcribed in the dorsal aorta at E8.0, serving to identify this as
the earliest recognized event in the developmental program leading to
differentiation of vascular SMCs from undifferentiated mesenchyme.
During postnatal development,
-galactosidase activity was restricted
to visceral and vascular SMCs. This pattern of distribution
recapitulates the expression pattern of the endogenous SM22
gene but
differs significantly from SM22
promoter-driven transgenic mice
(14, 19, 22, 43). SM22
-deficient mice are viable and
fertile and exhibit no obvious phenotypic abnormalities. SMC-containing tissues, including the vasculature, heart, uterus, stomach, intestine, and bladder, all developed normally. Consistent with these findings, the cytoskeletal organization of SM22
-deficient and wild-type vascular and visceral SMCs is virtually indistinguishable.
Our group and others have reported that the SM22
promoter restricts
expression of a lacZ reporter gene to arterial SMCs in transgenic mice (14, 19, 22, 43). In SM22
promoter-driven transgenic mice,
-galactosidase activity is not
observed in venous, coronary arterial, or visceral SMCs despite the
fact that the endogenous SM22
gene is expressed in these cells. This
led to the hypothesis that distinct transcriptional programs
distinguish tissue-restricted subsets of SMCs or SMC sublineages. This
hypothesis was supported by the finding that the smooth muscle
-actin promoter and intragenic enhancer (20), the
smooth muscle myosin heavy-chain promoter and intragenic enhancer
(21), the telokin promoter (10), and the
-enteric actin promoter (30) restrict transgene expression to unique tissue-restricted subsets of SMCs in transgenic mice. It is noteworthy that each of these transcriptional regulatory elements also contains a functionally important CArG box that binds
directly to the MADS box transcription factor SRF. The observed
-galactosidase activity in visceral and vascular SMCs of
SM22+/
LacZ mice is consistent with this model and leads
us to predict that additional, as-yet-unidentified, transcriptional
regulatory elements required for expression in venous, coronary
arterial, and visceral SMCs exist and are located in distant regions
flanking the SM22
gene. Identification and characterization of these
regulatory elements should provide fundamental insights into the
transcriptional programs that distinguish SMC sublineages.
Relatively little is currently understood about the transcriptional
programs and signaling pathways that regulate the specification of SMCs
from undifferentiated mesenchyme during embryonic development (for a
review, see references 27 and 28). The differentiation of
SMCs from mesenchyme is a critical event in angiogenic patterning that
ultimately distinguishes arteries, veins, and capillary beds. In the
mouse, SMC markers, including SM-
-actin, calponin, and SM22
, had
been detected as early as E9.5 in the dorsal aorta (27).
Therefore, we were surprised to detect
-galactosidase activity in
the dorsal aorta of E8.0 unturned SM22+/
LacZ embryos.
These data suggest that the signaling pathways that regulate the
specification and the differentiation of vascular SMCs from the
mesenchyme are activated earlier in the developing mouse embryo than
was recognized previously. As such, the SM22+/
LacZ mouse
and lacZ-tagged SMCs isolated from these mice may serve as
valuable experimental reagents for studying the molecular basis of SMC
differentiation. Moreover, because SM22
is downregulated in concert
with other contractile proteins in atherosclerotic lesions
(35-37), these mice may be used to examine the molecular mechanisms that modulate SMC phenotype and to examine the pathological mechanisms underlying vascular proliferative syndromes.
What then is the function of the cytoskeletal protein SM22
in SMCs
and other embryonic tissues, including the developing heart and
skeletal muscle? SM22
colocalizes with actin filaments and is
abundantly expressed in contractile SMCs. It has been conserved through
evolution and shows high-level sequence identity to the myofibrillar
regulatory protein calponin. However, SM22
-deficient mice are viable
and fertile and exhibit no overt phenotype. SMC-containing tissues,
including arteries, veins, heart, gut, uterus, and bladder, develop
normally. Basal homeostatic functions regulated in whole or in part by
SMCs, including the regulation of blood pressure, bladder control,
uterine contraction, and gastrointestinal motility, are not grossly
altered in SM22
-deficient mice. Consistent with these data, the SMC
ultrastructure and cytoskeletal organization in SM22
-deficient mice
is virtually indistinguishable from their control littermates. It
remains theoretically possible that SM22
is partially redundant with
another structurally related protein such as calponin. In this regard,
it is noteworthy that we recently cloned a novel mouse cDNA encoding a
protein with greater than 70% sequence identity to SM22
that is
also expressed in some SMC containing tissues (J. Zhang and M. Parmacek, unpublished data). Alternatively, SM22
may not be required
for basal homeostatic functions but may be required for stress
responses such as wound healing. The availability of SM22
-deficient
mice allows these and other possibilities to be examined.
 |
ACKNOWLEDGMENTS |
We thank Lisa Gottschalk for her help preparing the figures,
Angie Boyce for expert secretarial assistance, and Theodore J. Plappert
for technical assistance in performing echocardiography.
This project was supported in part by NIH NRSA grants HL10058 to B.P.H.
and NIH-R0156915 to M.S.P. M.S.P. is an Established Investigator of the
American Heart Association.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, University of Pennsylvania, 91234 Founders Pavilion, 3400 Spruce St., Philadelphia, PA 19104-4283. Phone: (215) 662-3140. Fax: (215) 349-8017. E-mail: parmacek{at}mail.med.upenn.edu.
 |
REFERENCES |
| 1.
|
Almendral, J. M.,
J. F. Santaren,
J. Perera,
M. Zerial, and R. Bravo.
1989.
Expression, cloning and cDNA sequence of a fibroblast serum-regulated gene encoding a putative actin-associated protein (p27).
Exp. Cell Res.
181:518-530[CrossRef][Medline].
|
| 2.
|
Ayme-Southgate, A.,
P. Lasko,
C. French, and M. L. Pardue.
1989.
Characterization of the gene for mp20: a Drosophila muscle protein that is not found in asynchronous oscillatory flight muscle.
J. Cell Biol.
108:521-531[Abstract/Free Full Text].
|
| 3.
|
Bradley, A.
1987.
Production and analysis of chimaeric mice, p. 113-151.
In
E. J. Robertson (ed.), Teratocarcinomas and embryonic stem cells: a practical approach. IRL Press, Oxford, England.
|
| 4.
|
Chan, Y. M.,
Q. C. Yu,
J. D. Fine, and E. Fuchs.
1993.
The genetic basis of Weber-Cockayne epidermolysis bullosa simplex.
Proc. Natl. Acad. Sci. USA
90:7414-7418[Abstract/Free Full Text].
|
| 5.
|
Chang, M. W.,
E. Barr,
J. Seltzer,
Y.-Q. Jiang,
G. J. Nabel,
E. G. Nabel,
M. S. Parmacek, and J. M. Leiden.
1995.
Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product.
Science
267:518-522[Abstract/Free Full Text].
|
| 6.
|
Duband, J. L.,
M. Gimona,
M. Scatena,
S. Sartore, and J. V. Small.
1993.
Calponin and SM22 as differentiation markers of smooth muscle: spatiotemporal distribution during avian embryonic development.
Differentiation
55:1-11[CrossRef][Medline].
|
| 7.
|
Fentzke, R. C.,
C. E. Korcarz,
R. M. Lang,
H. Lin, and J. M. Leiden.
1998.
Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart.
J. Clin. Investig.
101:2415-2426[Medline].
|
| 8.
|
Goetinck, S., and R. H. Waterston.
1994.
The Caenorhabditis elegans muscle-affecting gene unc-87 encodes a novel thin filament associated protein.
J. Cell Biol.
127:79-93[Abstract/Free Full Text].
|
| 9.
|
Helmke, B. P.,
R. D. Goldman, and P. F. Davies.
2000.
Rapid displacement of vimentin intermediate filaments in living cells exposed to flow.
Circ. Res.
86:745-752[Abstract/Free Full Text].
|
| 10.
|
Herring, B. P., and A. F. Smith.
1996.
Telokin expression is mediated by a smooth muscle cell-specific promoter.
Am J. Physiol.
270:C1656-C1665[Abstract/Free Full Text].
|
| 11.
|
Hiraoka, Y.,
J. W. Sedat, and D. A. Agard.
1990.
Determination of three-dimensional properties of a light microscope system: partial confocal behavior in epifluorescence microscopy.
Biophys. J.
57:325-333[Medline].
|
| 12.
|
Hogan, B.,
R. Beddington,
F. Constantini, and E. Lacy (ed.).
1994.
Manipulating the mouse embryo, 2nd ed.
Cold Spring Harbor Laboratory Press, Plainview, N.Y.
|
| 13.
|
James, A. L.,
P. D. Pare, and J. C. Hogg.
1989.
The mechanics of airway narrowing in asthma.
Am. Rev. Respir. Dis.
139:242-246[Medline].
|
| 14.
|
Kim, S.,
H. S. Ip,
M. M. Lu,
C. Clendenin, and M. S. Parmacek.
1997.
A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages.
Mol. Cell. Biol.
17:2266-2278[Abstract].
|
| 15.
|
Kuo, C. T.,
E. E. Morrisey,
R. Anandappa,
K. Sigrist,
M. M. Lu,
M. S. Parmacek,
C. Soudais, and J. M. Leiden.
1997.
GATA4 transcription factor is required for ventral morphogenesis and heart tube formation.
Genes Dev.
11:1048-1060[Abstract/Free Full Text].
|
| 16.
|
Lawson, D.,
M. Harrison, and C. Shapland.
1997.
Fibroblast transgelin and smooth muscle SM22 are the same protein, the expression of which is down-regulated in many cell lines.
Cell Motil. Cytoskel.
38:250-257[CrossRef][Medline].
|
| 17.
|
Lees-Miller, J. P.,
D. H. Heeley, and L. B. Smillie.
1987.
An abundant and novel protein of 22 kDa (SM22) is widely distributed in smooth muscles. Purification form bovine aorta.
Biochem. J.
244:705-709[Medline].
|
| 18.
|
Li, L.,
J. M. Miano,
P. Cserjesi, and E. N. Olson.
1996.
SM22 , a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis.
Circ. Res.
78:188-195[Abstract/Free Full Text].
|
| 19.
|
Li, L.,
J. M. Miano,
B. Mercer, and E. N. Olson.
1996.
Expression of the SM22 promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells.
J. Cell Biol.
132:849-859[Abstract/Free Full Text].
|
| 20.
|
Mack, C. P., and G. K. Owens.
1999.
Regulation of smooth muscle -actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions.
Circ. Res.
84:852-861[Abstract/Free Full Text].
|
| 21.
|
Madsen, C. S.,
R. C. P.,
J. E. Hungerford,
S. L. White,
I. Manabe, and G. K. Owens.
1998.
Smooth muscle-specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires 5'-flanking and first intronic DNA sequence.
Circ. Res.
82:908-917[Abstract/Free Full Text].
|
| 22.
|
Moessler, H.,
M. Mericskay,
Z. Li,
S. Nagl,
D. Paulin, and J. V. Small.
1996.
The SM22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice.
Development
122:2415-2425[Abstract].
|
| 23.
|
Morrisey, E. E.,
H. S. Ip,
Z. Tang, and M. S. Parmacek.
1997.
GATA-4 activates transcription via two novel domains that are conserved within the GATA-4/5/6 subfamily.
J. Biol. Chem.
272:8515-8524[Abstract/Free Full Text].
|
| 24.
|
Morrisey, E. E.,
Z. Tang,
K. Sigrist,
M. M. Lu,
F. Jiang,
H. S. Ip, and M. S. Parmacek.
1998.
GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo.
Genes Dev.
12:3579-3590[Abstract/Free Full Text].
|
| 25.
|
Newby, A. C., and A. B. Zaltsman.
1999.
Fibrous cap formation or destruction the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation.
Cardiovasc. Res.
41:345-360[Abstract/Free Full Text].
|
| 26.
|
North, A. J.,
M. Gimona,
Z. Lando, and J. V. Small.
1994.
Actin isoform compartments in chicken gizzard smooth muscle cells.
J. Cell. Sci.
107:445-455[Abstract].
|
| 27.
|
Owens, G. K.
1998.
Molecular control of vascular smooth muscle cell differentiation.
Acta Physiol. Scand.
164:623-635[Medline].
|
| 28.
| Parmacek, M. S. Transcriptional programs
regulating vascular smooth muscle cell development and differentiation.
Curr. Top. Dev. Biol., in press.
|
| 29.
|
Parmacek, M. S., and J. M. Leiden.
1989.
Structure and expression of the murine slow/cardiac troponin C gene.
J. Biol. Chem.
264:13217-13225[Abstract/Free Full Text].
|
| 30.
|
Qian, J.,
A. Kumar,
J. C. Szuscik, and J. L. Lessard.
1996.
Tissue and developmental specific expression of murine smooth muscle -actin fusion genes in transgenic mice.
Dev. Dyn.
207:135-144[CrossRef][Medline].
|
| 31.
|
Ren, W.,
G. Y. K. Ng,
R.-X. Wang,
P. H. Wu,
B. F. O'Dowd,
S. George,
D. H. Osmond, and C. Liew.
1994.
The identification of NP25: a novel protein that is differentially expressed by neuronal subpopulations.
Mol. Brain Res.
22:173-185[Medline].
|
| 32.
|
Ross, R.
1999.
Mechanisms of disease: atherosclerosis an inflammatory disease.
N. Engl. J. Med.
340:115-126[Free Full Text].
|
| 33.
|
Samaha, F. F.,
H. S. Ip,
E. E. Morrisey,
J. Seltzer,
Z. Tang,
J. Solway, and M. S. Parmacek.
1996.
Developmental pattern of expression and genomic organization of the calponin-h1 gene; a contractile smooth muscle cell marker.
J. Biol. Chem.
271:395-403[Abstract/Free Full Text].
|
| 34.
|
Schwartz, S. M., and C. E. Murry.
1998.
Proliferation and the monoclonal origins of atherosclerotic lesions.
Annu. Rev. Med.
49:437-460[CrossRef][Medline].
|
| 35.
|
Shanahan, C. M.,
N. R. B. Cary,
J. C. Metcalfe, and P. L. Weissberg.
1994.
High expression of genes for calcification-regulating proteins in human atherosclerotic plaques.
J. Clin. Investig.
93:2393-2402.
|
| 36.
|
Shanahan, C. M., and P. L. Weissberg.
1997.
Smooth muscle cell heterogeneity: Patterns of gene expression in vascular smooth muscle cells in vitro and in vivo.
Arterioscler. Thromb. Vasc. Biol.
183:333-338.
|
| 37.
|
Shanahan, C. M.,
P. L. Weissberg, and J. C. Metcalfe.
1993.
Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells.
Circ. Res.
73:193-204[Abstract].
|
| 38.
|
Shapland, C.,
J. J. Hsuan,
N. F. Totty, and D. Lawson.
1993.
Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein.
J. Cell Biol.
121:1065-1073[Abstract/Free Full Text].
|
| 39.
|
Shapland, C.,
P. Lowings, and D. Lawson.
1988.
Identification of new actin-associated polypeptides that are modified by viral transformation and changes in cell shape.
J. Cell Biol.
107:153-161[Abstract/Free Full Text].
|
| 40.
|
Small, J. V.
1985.
Geometry of actin-membrane attachments in the smooth muscle cell: the localisations of vinculin and -actinin.
EMBO J.
4:45-49[Medline].
|
| 41.
|
Small, J. V., and M. Gimona.
1998.
The cytoskeleton of the vertebrate smooth muscle cell.
Acta Physiol. Scand.
164:341-348[CrossRef][Medline].
|
| 42.
|
Small, J. V., and A. Sobieszek.
1977.
Studies on the function and composition of the 10-nm (100-A) filaments of vertebrate smooth muscle.
J. Cell Sci.
23:243-268[Abstract/Free Full Text].
|
| 43.
|
Solway, J.,
J. Seltzer,
F. F. Samaha,
S. Kim,
L. E. Alger,
Q. Niu,
E. E. Morrisey,
H. S. Ip, and M. S. Parmacek.
1995.
Structure and expression of a smooth muscle cell-specific gene, SM22 .
J. Biol. Chem.
270:13460-13469[Abstract/Free Full Text].
|
| 44.
|
Takahashi, K., and B. Nadal-Ginard.
1991.
Molecular cloning and sequence analysis of smooth muscle calponin.
J. Biol. Chem.
266:13284-13288[Abstract/Free Full Text].
|
| 45.
|
Thweatt, R.,
C. K. Lumpkin, and S. Goldstein.
1992.
A novel gene encoding a smooth muscle protein is overexpressed in senescent human fibroblasts.
Biochem. Biophys. Commun.
187:1-7[CrossRef][Medline].
|
| 46.
|
Tybulewicz, V. L. J.,
C. E. Crawford,
P. K. Jackson,
R. T. Bronson, and R. C. Mulligan.
1991.
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene.
Cell
65:1153-1163[CrossRef][Medline].
|
Molecular and Cellular Biology, February 2001, p. 1336-1344, Vol. 21, No. 4
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.2001.21.4.1336-1344.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Leguillette, R., Laviolette, M., Bergeron, C., Zitouni, N., Kogut, P., Solway, J., Kachmar, L., Hamid, Q., Lauzon, A.-M.
(2009). Myosin, Transgelin, and Myosin Light Chain Kinase: Expression and Function in Asthma. Am. J. Respir. Crit. Care Med.
179: 194-204
[Abstract]
[Full Text]
-
Shi, S., Yu, L., Chiu, C., Sun, Y., Chen, J., Khitrov, G., Merkenschlager, M., Holzman, L. B., Zhang, W., Mundel, P., Bottinger, E. P.
(2008). Podocyte-Selective Deletion of Dicer Induces Proteinuria and Glomerulosclerosis. J. Am. Soc. Nephrol.
19: 2159-2169
[Abstract]
[Full Text]
-
Goodwin, J. E., Zhang, J., Geller, D. S.
(2008). A Critical Role for Vascular Smooth Muscle in Acute Glucocorticoid-Induced Hypertension. J. Am. Soc. Nephrol.
19: 1291-1299
[Abstract]
[Full Text]
-
Yu, H., Konigshoff, M., Jayachandran, A., Handley, D., Seeger, W., Kaminski, N., Eickelberg, O.
(2008). Transgelin is a direct target of TGF-{beta}/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J.
22: 1778-1789
[Abstract]
[Full Text]
-
Wasteson, P., Johansson, B. R., Jukkola, T., Breuer, S., Akyurek, L. M., Partanen, J., Lindahl, P.
(2008). Developmental origin of smooth muscle cells in the descending aorta in mice. Development
135: 1823-1832
[Abstract]
[Full Text]
-
Leguillette, R., Lauzon, A.-M.
(2008). Molecular Mechanics of Smooth Muscle Contractile Proteins in Airway Hyperresponsiveness and Asthma. Proc Am Thorac Soc
5: 40-46
[Abstract]
[Full Text]
-
Carvalho, R. L. C., Itoh, F., Goumans, M.-J., Lebrin, F., Kato, M., Takahashi, S., Ema, M., Itoh, S., van Rooijen, M., Bertolino, P., ten Dijke, P., Mummery, C. L.
(2007). Compensatory signalling induced in the yolk sac vasculature by deletion of TGF receptors in mice. J. Cell Sci.
120: 4269-4277
[Abstract]
[Full Text]
-
Compton, L. A., Potash, D. A., Brown, C. B., Barnett, J. V.
(2007). Coronary Vessel Development Is Dependent on the Type III Transforming Growth Factor {beta} Receptor. Circ. Res.
101: 784-791
[Abstract]
[Full Text]
-
Schmidt, J. A., Avila, J. M. d., McLean, D. J.
(2007). Analysis of Gene Expression in Bovine Testis Tissue Prior to Ectopic Testis Tissue Xenografting and During the Grafting Period. Biol. Reprod.
76: 1071-1080
[Abstract]
[Full Text]
-
Umans, L., Cox, L., Tjwa, M., Bito, V., Vermeire, L., Laperre, K., Sipido, K., Moons, L., Huylebroeck, D., Zwijsen, A.
(2007). Inactivation of Smad5 in Endothelial Cells and Smooth Muscle Cells Demonstrates that Smad5 Is Required for Cardiac Homeostasis. Am. J. Pathol.
170: 1460-1472
[Abstract]
[Full Text]
-
Nair, R. R., Solway, J., Boyd, D. D.
(2006). Expression Cloning Identifies Transgelin (SM22) as a Novel Repressor of 92-kDa Type IV Collagenase (MMP-9) Expression. J. Biol. Chem.
281: 26424-26436
[Abstract]
[Full Text]
-
Proweller, A., Tu, L., Lepore, J. J., Cheng, L., Lu, M. M., Seykora, J., Millar, S. E., Pear, W. S., Parmacek, M. S.
(2006). Impaired Notch Signaling Promotes De novo Squamous Cell Carcinoma Formation.. Cancer Res.
66: 7438-7444
[Abstract]
[Full Text]
-
Balza, R. O. Jr., Misra, R. P.
(2006). Role of the Serum Response Factor in Regulating Contractile Apparatus Gene Expression and Sarcomeric Integrity in Cardiomyocytes. J. Biol. Chem.
281: 6498-6510
[Abstract]
[Full Text]
-
El-Mounayri, O., Triplett, J. W., Yates, C. W., Herring, B. P.
(2005). Regulation of Smooth Muscle-specific Gene Expression by Homeodomain Proteins, Hoxa10 and Hoxb8. J. Biol. Chem.
280: 25854-25863
[Abstract]
[Full Text]
-
Owens, G. K., Kumar, M. S., Wamhoff, B. R.
(2004). Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease. Physiol. Rev.
84: 767-801
[Abstract]
[Full Text]
-
Feil, S., Hofmann, F., Feil, R.
(2004). SM22{alpha} Modulates Vascular Smooth Muscle Cell Phenotype During Atherogenesis. Circ. Res.
94: 863-865
[Abstract]
[Full Text]
-
Kaplan-Albuquerque, N., Garat, C., Van Putten, V., Nemenoff, R. A.
(2003). Regulation of SM22{alpha} expression by arginine vasopressin and PDGF-BB in vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol.
285: H1444-H1452
[Abstract]
[Full Text]
-
Du, K. L., Ip, H. S., Li, J., Chen, M., Dandre, F., Yu, W., Lu, M. M., Owens, G. K., Parmacek, M. S.
(2003). Myocardin Is a Critical Serum Response Factor Cofactor in the Transcriptional Program Regulating Smooth Muscle Cell Differentiation. Mol. Cell. Biol.
23: 2425-2437
[Abstract]
[Full Text]
-
Xu, R., Ho, Y.-S., Ritchie, R. P., Li, L.
(2003). Human SM22alpha BAC encompasses regulatory sequences for expression in vascular and visceral smooth muscles at fetal and adult stages. Am. J. Physiol. Heart Circ. Physiol.
284: H1398-H1407
[Abstract]
[Full Text]
-
Shu, W., Jiang, Y. Q., Lu, M. M., Morrisey, E. E.
(2003). Wnt7b regulates mesenchymal proliferation and vascular development in the lung. Development
129: 4831-4842
[Abstract]
[Full Text]
-
Li, W. E. I., Waldo, K., Linask, K. L., Chen, T., Wessels, A., Parmacek, M. S., Kirby, M. L., Lo, C. W.
(2003). An essential role for connexin43 gap junctions in mouse coronary artery development. Development
129: 2031-2042
[Abstract]
[Full Text]
-
Chen, S., Kulik, M., Lechleider, R. J.
(2003). Smad proteins regulate transcriptional induction of the SM22{alpha} gene by TGF-{beta}. Nucleic Acids Res
31: 1302-1310
[Abstract]
[Full Text]
-
Wulfkuhle, J. D., Sgroi, D. C., Krutzsch, H., McLean, K., McGarvey, K., Knowlton, M., Chen, S., Shu, H., Sahin, A., Kurek, R., Wallwiener, D., Merino, M. J., Petricoin, E. F. III, Zhao, Y., Steeg, P. S.
(2002). Proteomics of Human Breast Ductal Carcinoma in Situ. Cancer Res.
62: 6740-6749
[Abstract]
[Full Text]
-
Desjardins, P. R., Burkman, J. M., Shrager, J. B., Allmond, L. A., Stedman, H. H.
(2002). Evolutionary Implications of Three Novel Members of the Human Sarcomeric Myosin Heavy Chain Gene Family. Mol Biol Evol
19: 375-393
[Abstract]
[Full Text]
-
Morgan, K. G., Gangopadhyay, S. S.
(2001). Signal Transduction in Smooth Muscle: Invited Review: Cross-bridge regulation by thin filament-associated proteins. J. Appl. Physiol.
91: 953-962
[Abstract]
[Full Text]
-
Strobeck, M., Kim, S., Zhang, J. C. L., Clendenin, C., Du, K. L., Parmacek, M. S.
(2001). Binding of Serum Response Factor to CArG Box Sequences Is Necessary but Not Sufficient to Restrict Gene Expression to Arterial Smooth Muscle Cells. J. Biol. Chem.
276: 16418-16424
[Abstract]
[Full Text]
-
Steitz, S. A., Speer, M. Y., Curinga, G., Yang, H.-Y., Haynes, P., Aebersold, R., Schinke, T., Karsenty, G., Giachelli, C. M.
(2001). Smooth Muscle Cell Phenotypic Transition Associated With Calcification: Upregulation of Cbfa1 and Downregulation of Smooth Muscle Lineage Markers. Circ. Res.
89: 1147-1154
[Abstract]
[Full Text]